Any chronic illness diagnosis is scary and confusing. It is a time filled with an abundance of emotions that are difficult to navigate. Unfortunately, these emotions don’t exist only for the first few months after a diagnosis, but rather they remain ever-present as a patient learns to live…
Letting Go of Guilt as a Patient with Pulmonary Fibrosis
A recent study has provided more insight into the molecular processes that might be involved in the pathological changes that take place in the lungs of patients with idiopathic pulmonary fibrosis (IPF). In the study, “A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis,”…
I’ll be transparent: Living with a chronic illness sucks, regardless of the disease you deal with. It’s not easy learning to navigate life while sick, and unfortunately, there is no rulebook to study. I can only speak for all the difficulties that come with having idiopathic pulmonary fibrosis…
Pliant Therapeutics announced that its lead therapy candidate PLN-74809 was designated an orphan drug by the U.S. Food and Drug Administration (FDA), an act that helps to advance its development as a possible treatment of…
Being diagnosed with pulmonary fibrosis is not for the faint of heart. It is a rough road full of fears, losses, and unknowns. It’s difficult getting used to all that comes with this diagnosis, including lots of up and downs, tears, disbelief, and attempts to adjust. Taking good care…
Adding Ofev (nintedanib) to Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) is tolerated by most patients and has a similar safety profile as taking each medication alone,…
The presence of swollen lymph nodes in patients with idiopathic pulmonary fibrosis (IPF) at the time of their diagnosis can be a predictor of poor prognosis, associated with stronger disease severity and lower survival, a study suggests.
Do NOX enzymes play a pivotal role in idiopathic pulmonary fibrosis (IPF)? This is the question researchers hope to answer with a newly funded research program evaluating the role of NOX enzymes. Genkyotex, a company focused on developing therapies for chronic diseases, recently announced that the U.S. National Institutes of…
Editor’s note: A continuation of Charlene Marshall’s monthly “Gratitude Miniseries.” Similar to my “Gratitude Miniseries” column for April, July was not one of my favorite months this year. While some good things happened, which I will highlight below, I had to navigate many social and emotional challenges…
The Pulmonary Fibrosis Foundation (PFF) has completed the enrollment of PF patients in its PFF Patient Registry, with the admission of the 2,002nd patient. Launched in 2016, the PFF Patient Registry was created to compile large quantities of data collected from anonymous PF patients, and use it to help…
